Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

Oxaliplatin 6Irinotecan 5Fluorouracil 5Bevacizumab 4Leucovorin 3Drug Therapy 3Capecitabine 35,10-methylenetetrahydrofolic acid 3pembrolizumab 2Ocoxin 2Magnetic Resonance Spectroscopy 2Levoleucovorin 2Folfox protocol 2Cyclophosphamide 2Cetuximab 2trifluridine tipiracil drug combination 1sintilimab 1repotrectinib 1pralsetinib 1penpulimab 1napabucasin 1huachansu 1guadecitabine 1golotimod 1encorafenib 1alectinib 1XELOX 1Ursodeoxycholic Acid 1Surveys and Questionnaires 1S-1 plus cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Diseases × sintilimab × Clear all
NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡